IRADIMED CORPORATION (IRMD) Stock Price & Analysis

IRADIMED CORPORATION (IRMD) closed at USD 83.93 on Wednesday, October 28, 2026, down 0.02% on the day. The US market is currently closed (after-hours); this is not a live price.

The prior close was USD 83.95; the Oct 28, 2026 session ranged USD 83.56–85.03 on volume of 161,626 shares. Market capitalization is $1.07B, with a 52-week range of USD 75.75–107.9 (NGM). Source: Nexqual, retrieved October 28, 2026 at 21:06 UTC.

Also available as compact Markdown for AI agents: nexqual.com/IRMD.md

Key facts (IRMD)

• Last four reported quarters (through Jun 30, 2026): revenue $86.3M, net income $23.1M (26.7% margin), free cash flow $25.1M (SEC filings).
• Valuation: P/E 46.6x (avg 42.4x at the last 3 fiscal year-ends).
• Insider open-market sales, last ~7 months: 10 Form 4 filings, $5.3M; 2 not under a Rule 10b5-1 plan ($408K); 1 by opportunistic insiders (1 outside 10b5-1 plans), 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Buy (mean 2.33 on a 1–5 scale) (3 analysts), mean target USD 118 (range 116–120).
• Total return with dividends: 1Y +8.7% vs S&P 500 +13.6%; 5Y +147.6% vs S&P 500 +79.8%.
• Next earnings: 2026-10-30, EPS estimate USD 0.55, revenue estimate $23.4M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (IRMD)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (IRMD)

P/E 46.6x · P/S 12.4x · P/FCF 42.7x · P/B 10.6x · FCF yield 2.34% · Earnings yield 2.15% · Dividend yield (paid, TTM) 1.48%

P/E at fiscal year-ends: Dec 2025 55.6x, Dec 2024 36.6x, Dec 2023 35.1x.

Insider sales (SEC Form 4, open-market, last ~7 months) (IRMD)

8 of 10 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (IRMD)

Consensus Buy (mean 2.33 on a 1–5 scale), 3 analysts; mean target USD 118 (low 116, high 120).

Rating changes, last 120 days:

Total return (dividends reinvested) (IRMD)

IRMD earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

IRMD recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

IRMD revenue by product line (quarter ended Jun 30, 2026)

IRMD revenue by region (quarter ended Jun 30, 2026)

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

IRMD company outlook (results filed May 1, 2026)

• “We expect significant shipments to begin in the second quarter of 2026 as we transition our customers to the new platform, with the third quarter reflecting the full impact of 3870 shipments and revenue growth accelerating through the back half of the year.”

Quoted word-for-word from the SEC 8-K results press release.

IRMD analyst estimates and revisions

IRMD options: expected move

Options price a move of about ±8.5% (±$7.15) by Nov 20, 2026, which includes earnings on Oct 30, 2026. Over the last 8 reports the stock moved ±8.5% on average.

30-day implied volatility 35.1% vs 21.5% realized over the last 30 trading days. Put/call ratio (volume) —. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 28, 2026 at 21:06 UTC)

Technical Analysis (IRMD)

Nexqual's technical model rates IRMD "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 28, 2026 at 21:06 UTC.

Analyst Ratings (IRMD)

Wall Street analysts rate IRMD "Buy" based on 3 analysts, with a mean price target of USD 118 (range USD 116–120), per Nexqual as of October 28, 2026 at 21:06 UTC.

Earnings (IRMD)

Recent Earnings History

Source: Nexqual, October 28, 2026 at 21:06 UTC.

Financials & Fundamentals (IRMD)

Source: Nexqual, October 28, 2026 at 21:06 UTC.

Financial Health Score (IRMD)

Nexqual rates IRADIMED CORPORATION's overall financial health "Solid" across five dimensions, as of October 28, 2026 at 21:06 UTC.

Ownership (IRMD)

Source: Nexqual, October 28, 2026 at 21:06 UTC.

Leadership (IRMD)

IRADIMED CORPORATION is led by Roger E. Susi, Founder, Chairman, CEO & President, per Nexqual as of October 28, 2026 at 21:06 UTC.

Major Backers & Investors (IRMD)

Notable institutional backers of IRADIMED CORPORATION include Kayne Anderson Rudnick Investment Management LLC, Renaissance Technologies, Copeland Capital Management, LLC, according to Nexqual as of October 28, 2026 at 21:06 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 28, 2026 at 21:06 UTC.

From IRADIMED CORPORATION's Latest SEC 10-K Filing (filed 2026-03-06)

Key Strengths & Strategy (as disclosed to the SEC)

• The MRidium 3870 IV Infusion Pump System consists of the MRidium 3870 MRI Compatible IV Infusion Pump, a non-magnetic IV pole mounting system, a non-magnetic mobile IV pole stand, proprietary disposable IV tubing sets and other options including a Remote Display Unit.
• Our patented MRidium 3870 MRI Compatible IV Infusion Pump System, introduced in 2025, has been designed with a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts, touch screen user interface, and other special features to safely and predictably deliver anesthesia and other critical care IV fluids during various MRI procedures.
• Our patented MRidium 3860+ IV Infusion Pump System has been designed with a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures.
• The MRidium 3860+ IV Infusion Pump System consists of an MRidium MRI compatible IV infusion pump, non-magnetic mobile stand, proprietary disposable IV tubing sets and many of these systems contain additional optional upgrade accessories.

Partnerships

• To deal with the harsh environment of MR, some manufacturers have offered a "shielded box" solution (also known as a "Faraday cage") for use with their standard IV pumps, but the approach has not been widely accepted by customers.
• For example, the non-magnetic, ultrasonic motor which drives our MRI compatible IV infusion pump was sole sourced from a major multinational Japanese manufacturing company until December 2024 when the Company chose to enter into a technology transfer and license agreement with the supplier allowing the Company to manufacture its own non-magnetic, ultrasonic motors.

Legal & Regulatory Risks (Item 1A, quoted)

• The manufacture of our products requires strict adherence to regulatory requirements governing medical devices and if we or our suppliers encounter problems our business could suffer.
• We are subject to substantial government regulation and trade policies that are subject to change and could force us to make modifications to how we develop, manufacture, market, and price our products.
• We may incur product liability losses or become subject to other lawsuits related to our products, business, and insurance coverage could be inadequate or unavailable to cover these losses.
• We are subject to healthcare fraud and abuse regulations that could result in significant liability, require us to change our business practices and restrict our operations in the future.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 28, 2026 at 21:06 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt